More on VRXA
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.73 |
|
|||
| Open | $1.77 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $2.42 | ||||
| Day Low | $1.77 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 5,055,430 | ||||
- Veraxa Biotech starts cell line development with ATUM for cancer therapy
- VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
- VERAXA Biotech expands lab space at Heidelberg R&D site
- VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
- VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
- VERAXA Biotech reports in vitro data for its BiTAC-ADC platform
- VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
- VERAXA Biotech completes merger, begins NASDAQ trading
- VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026
Entities mentioned with VRXA
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- SPAC | View Related Stories »
- Cantor Fitzgerald | View Related Stories »
- IPO | View Related Stories »
- Show More...
